Nabilone for the treatment of pain in fibromyalgia
Nabilone for the treatment of pain in fibromyalgia
复制标题
DOI：
10.1016/j.jpain.2007.09.002
复制
发表时间：
2008-02-01
期刊：
影响因子：
4
通讯作者：
Perry, Daryl
中科院分区：
文献类型：
--
作者：
Skrabek, Ryan Quinlan;Gallmova, Lena;Perry, Daryl
进行了一项随机、双盲、安慰剂对照试验，以确定40例纤维肌痛患者使用纳比隆进行疼痛管理和改善生活质量的益处。在基线评估后，受试者在4周内从睡前0.5 mg PO滴定至1 mg BID或接受相应的安慰剂。在2周和4周访视时，评价了主要结局指标疼痛视觉模拟量表（VAS）和次要结局指标压痛点数量、平均压痛点疼痛阈值和纤维肌痛影响问卷（FIQ）。4周洗脱期后，受试者返回重新评估结局指标。基线时，两组之间的人口统计学无显著差异。VAS评分明显下降（-2.04，P
A randomized, double-blind, placebo-controlled trial was conducted to determine the benefit of nabilone in pain management and quality of life improvement in 40 patients with fibromyalgia. After a baseline assessment, subjects were titrated up on nabilone, from 0.5 mg PO at bedtime to 1 mg BID over 4 weeks or received a corresponding placebo. At the 2- and 4-week visits, the primary outcome measure, visual analog scale (VAS) for pain, and the secondary outcome measures, number of tender points, the average tender point pain threshold, and the Fibromyalgia Impact Questionnaire (FIQ), were evaluated. After a 4-week washout period, subjects returned for reassessment of the outcome measures. There were no significant differences in population demographics between groups at baseline. There were significant decreases in the VAS (-2.04, P